KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Land & Improvements: 2014-2016

Historic Land & Improvements for Jazz Pharmaceuticals (JAZZ) over the last 2 years, with Mar 2016 value amounting to $1.8 million.

  • Jazz Pharmaceuticals' Land & Improvements rose 33.19% to $1.8 million in Q1 2016 from the same period last year, while for Mar 2016 it was $1.8 million, marking a year-over-year increase of 33.19%. This contributed to the annual value of $1.8 million for FY2015, which is 14.74% up from last year.
  • As of Q1 2016, Jazz Pharmaceuticals' Land & Improvements stood at $1.8 million, which was up 3.55% from $1.8 million recorded in Q4 2015.
  • Jazz Pharmaceuticals' 5-year Land & Improvements high stood at $1.8 million for Q1 2016, and its period low was $1.4 million during Q1 2015.
  • Its 3-year average for Land & Improvements is $1.7 million, with a median of $1.7 million in 2014.
  • Per our database at Business Quant, Jazz Pharmaceuticals' Land & Improvements decreased by 17.76% in 2015 and then spiked by 33.19% in 2016.
  • Quarterly analysis of 3 years shows Jazz Pharmaceuticals' Land & Improvements stood at $1.5 million in 2014, then rose by 14.74% to $1.8 million in 2015, then spiked by 33.19% to $1.8 million in 2016.
  • Its Land & Improvements stands at $1.8 million for Q1 2016, versus $1.8 million for Q4 2015 and $1.8 million for Q3 2015.